932 related articles for article (PubMed ID: 27349705)
1. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
[TBL] [Abstract][Full Text] [Related]
2. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Hagiwara N; Kawada-Watanabe E; Koyanagi R; Arashi H; Yamaguchi J; Nakao K; Tobaru T; Tanaka H; Oka T; Endoh Y; Saito K; Uchida T; Matsui K; Ogawa H
Eur Heart J; 2017 Aug; 38(29):2264-2276. PubMed ID: 28430910
[TBL] [Abstract][Full Text] [Related]
3. Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome.
Im J; Kawada-Watanabe E; Yamaguchi J; Arashi H; Otsuki H; Matsui Y; Sekiguchi H; Fujii S; Mori F; Ogawa H; Hagiwara N
Sci Rep; 2021 Apr; 11(1):7480. PubMed ID: 33820931
[TBL] [Abstract][Full Text] [Related]
4. Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER.
Yamaguchi J; Kawada-Watanabe E; Koyanagi R; Arashi H; Sekiguchi H; Nakao K; Tobaru T; Tanaka H; Oka T; Endo Y; Saito K; Uchida T; Matsui K; Ogawa H; Hagiwara N
Atherosclerosis; 2018 Jul; 274():139-145. PubMed ID: 29772482
[TBL] [Abstract][Full Text] [Related]
5. Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Arashi H; Yamaguchi J; Kawada-Watanabe E; Koyanagi R; Sekiguchi H; Mori F; Haruta S; Ishii Y; Murasaki S; Suzuki K; Yamauchi T; Ogawa H; Hagiwara N
J Am Heart Assoc; 2019 Aug; 8(16):e012953. PubMed ID: 31390907
[TBL] [Abstract][Full Text] [Related]
6. The Effects of Lipid-Lowering Therapy on Serum Eicosapentaenoic Acid to Arachidonic Acid Ratio: An HIJ-PROPER Sub-Analysis.
Arashi H; Yamaguchi J; Kawada-Watanabe E; Otsuki H; Sekiguchi H; Ogawa H; Hagiwara N
J Cardiovasc Pharmacol Ther; 2020 Nov; 25(6):548-555. PubMed ID: 32567339
[TBL] [Abstract][Full Text] [Related]
7. Effect of Ezetimibe + Pitavastatin on Cardiovascular Outcomes in Patients with ST-Segment Elevation Myocardial Infarction (from the HIJ-PROPER Study).
Otsuki H; Arashi H; Yamaguchi J; Kawada-Watanabe E; Ogawa H; Hagiwara N
Am J Cardiol; 2020 Oct; 132():15-21. PubMed ID: 32773226
[TBL] [Abstract][Full Text] [Related]
8. Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.
Kawada-Watanabe E; Yamaguchi J; Sekiguchi H; Arashi H; Ogawa H; Hagiwara N
J Cardiol; 2020 May; 75(5):500-506. PubMed ID: 31699568
[TBL] [Abstract][Full Text] [Related]
9. Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
Nakazawa M; Arashi H; Yamaguchi J; Ogawa H; Hagiwara N
Atherosclerosis; 2020 Jun; 303():21-28. PubMed ID: 32474302
[TBL] [Abstract][Full Text] [Related]
10. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
[TBL] [Abstract][Full Text] [Related]
11. Effect of Aggressive Lipid-Lowering Therapy in Single-Vessel vs. Multivessel Coronary Artery Disease Patients With Acute Coronary Syndrome - Heart Institute of Japan-Proper Level of Lipid Lowering With Pitavastatin and Ezetimibe in Acute Coronary Syndrome (HIJ-PROPER) Substudy.
Ogiso M; Yamaguchi J; Kawada-Watanabe E; Koyanagi R; Sekiguchi H; Sakamoto T; Iguchi N; Tanaka H; Okada H; Ota Y; Jujo K; Fujii S; Ogawa H; Hagiwara N
Circ Rep; 2020 Jan; 2(2):128-134. PubMed ID: 33693218
[No Abstract] [Full Text] [Related]
12. Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
Hiro T; Hirayama A; Ueda Y; Komatsu S; Matsuoka H; Takayama T; Ishihara M; Hayashi T; Saito S; Kodama K;
J Cardiol; 2014 Dec; 64(6):501-7. PubMed ID: 24725763
[TBL] [Abstract][Full Text] [Related]
13. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
[TBL] [Abstract][Full Text] [Related]
14. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial.
Taguchi I; Iimuro S; Iwata H; Takashima H; Abe M; Amiya E; Ogawa T; Ozaki Y; Sakuma I; Nakagawa Y; Hibi K; Hiro T; Fukumoto Y; Hokimoto S; Miyauchi K; Yamazaki T; Ito H; Otsuji Y; Kimura K; Takahashi J; Hirayama A; Yokoi H; Kitagawa K; Urabe T; Okada Y; Terayama Y; Toyoda K; Nagao T; Matsumoto M; Ohashi Y; Kaneko T; Fujita R; Ohtsu H; Ogawa H; Daida H; Shimokawa H; Saito Y; Kimura T; Inoue T; Matsuzaki M; Nagai R
Circulation; 2018 May; 137(19):1997-2009. PubMed ID: 29735587
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
17. COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME.
Japaridze L; Sadunishvili M; Megreladze I
Georgian Med News; 2016 Mar; (252):15-22. PubMed ID: 27119829
[TBL] [Abstract][Full Text] [Related]
18. Lipid Management and 2-Year Clinical Outcomes in Japanese Patients with Acute Coronary Syndrome: EXPLORE-J.
Nakamura M; Ako J; Arai H; Hirayama A; Nohara A; Murakami Y; Ozaki A; Harada-Shiba M
J Atheroscler Thromb; 2021 Dec; 28(12):1307-1322. PubMed ID: 33612707
[TBL] [Abstract][Full Text] [Related]
19. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
20. Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Hibi K; Sonoda S; Kawasaki M; Otsuji Y; Murohara T; Ishii H; Sato K; Koshida R; Ozaki Y; Sata M; Morino Y; Miyamoto T; Amano T; Morita S; Kozuma K; Kimura K; Fujiwara H;
Circ J; 2018 Feb; 82(3):757-766. PubMed ID: 29212965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
